Schizophrenia News

Individuals with a predelivery history of concussion appeared to be at increased risk for severe maternal mental illness, highlighting the importance of screening and supportive care for this high-risk group, according to researchers.

SAN ANTONIO —An intestinal microsomal triglyceride transfer protein inhibitor reduced postprandial triglycerides and halted weight gain in patients treated with the antipsychotic olanzapine, according to results of a pilot study.

According to published results, severe mental illnesses, such as schizophrenia and bipolar disorder, may be risk factors for decreased bone mineral density, fragility fractures and undiagnosed osteoporosis.

Antipsychotics differed in their efficacy in preventing relapse hospitalization and treatment failure among patients with schizophrenia spectrum disorder, according to research published in JAMA Network Open.

Adults with a schizophrenia spectrum disorder had increased risk for severe infection outcomes while exposed to antipsychotics compared with nonexposure periods, according to a study published in The Lancet Psychiatry.

Obscured by the celebratory congratulations and profuse praise of the scientific advance marked by the FDA’s approval of KarXT, now branded Cobenfy, is the revealing and instructive story of how this novel therapeutic agent came to fruition.

The FDA has approved Cobenfy, formerly known as KarXT, a muscarinic acetylcholine receptor agonist for the treatment of schizophrenia in adults.

Among patients with schizophrenia, TV-46000 had a favorable safety profile that was consistent with other formulations of risperidone and previous studies of TV-46000, according to a study published in CNS Drugs.

NEW YORK — In this Healio Video Perspective, Hyun Jung Kim, MD, discusses the format of her presentation on the relationship between cannabis use and risk for psychosis at the American Psychiatric Association Annual Meeting.